Rituxan deaths reported to FDA

The deaths of two women being treated with Genentech's Rituxan (rituximab) for systemic lupus erythematosus have been reported to the FDA. The agency is working with the company to obtain additional info and to strengthen the warnings in the product labeling.

You must be a registered member of MMM to post a comment.

Next Article in Legal/Regulatory


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.